Takeda Pharmaceutical Full Year 2025 Earnings: EPS Misses Expectations

Simply Wall St · 06/26 21:41

Takeda Pharmaceutical (TSE:4502) Full Year 2025 Results

Key Financial Results

  • Revenue: JP¥4.58t (up 7.5% from FY 2024).
  • Net income: JP¥107.9b (down 25% from FY 2024).
  • Profit margin: 2.4% (down from 3.4% in FY 2024).
  • EPS: JP¥68.36 (down from JP¥92.09 in FY 2024).

4502 Products In Clinical Trials

  • Phase I: 5.
  • Phase II: 11.
  • Phase III: 20.

4502 Post-Clinical Trial Products

  • Pre-registration: 5.
  • Approved (during full year): 11.
revenue-and-expenses-breakdown
TSE:4502 Revenue and Expenses Breakdown June 26th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Takeda Pharmaceutical EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 19%.

The primary driver behind last 12 months revenue was the United States segment contributing a total revenue of JP¥2.38t (52% of total revenue). The largest operating expense was General & Administrative costs, amounting to JP¥1.10t (38% of total expenses). Explore how 4502's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are up 1.4% from a week ago.

Risk Analysis

You should learn about the 4 warning signs we've spotted with Takeda Pharmaceutical.